Back to search

Peptide record

TPDB09495

Antibacterial Antifungal Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09495
Antibacterial Antifungal Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Antifungal, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KFFKKLKKAVKKGFKKFAKV
Physicochemical Analysis
C120H200N30O21
RNDCEQHIMPSTWY
K
2399.10
11.46
10
0
9
+10
4.63
-0.620
58.50
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
1
L
10
K
0
M
4
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 10 M: 0 F: 4 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
20
C120H200N30O21
2399.10
11.46
+10
4.63
-0.620
Evidence Records 29 records
Evidence 1 Activity

Activity

MIC
Antibacterial
>100 µg/mL

Target

E.cloacae

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli ATCC 25922 or ML-35p or 6 clincal strains (1.56-12.5 ug/ml), E.cloacae (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC
Evidence 2 Activity

Activity

MIC
Antibacterial
12.5 µg/mL

Target

Enterobacter aerogenes

Source & Reference

dbAMP DRAMP

Other

ATCC 25922 or ML-35p or 6 clincal strains (1.56-12.5 ug/ml), E.cloacae (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC 3.1-6.25 ug/ml), K. pneumoniae
Evidence 3 Activity

Activity

MIC
Antibacterial
6.25-12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

l strains (1.56-12.5 ug/ml), E.cloacae (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC 3.1-6.25 ug/ml), K. pneumoniae (3.1-6.25 ug/ml), Gram+ S. aureus ATCC
Evidence 4 Activity

Activity

MIC
Antibacterial
3.1-6.25 µg/mL

Target

H. influenzae

Source & Reference

dbAMP DRAMP

Other

e (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC 3.1-6.25 ug/ml), K. pneumoniae (3.1-6.25 ug/ml), Gram+ S. aureus ATCC 25923, ATCC 43300 MRSA (MIC 3.125-1
Evidence 5 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP DRAMP

Other

iae (3.1-6.25 ug/ml), Gram+ S. aureus ATCC 25923, ATCC 43300 MRSA (MIC 3.125-12.5 ug/ml), E. faecalis ATCC 29212 (MIC 25 ug/ml), and fungi: C.albicans (MIC >200 ug/ml).
Evidence 6 Activity

Activity

MIC
Antibacterial
>200 µg/mL

Target

C.albicans

Source & Reference

dbAMP DRAMP

Other

ATCC 43300 MRSA (MIC 3.125-12.5 ug/ml), E. faecalis ATCC 29212 (MIC 25 ug/ml), and fungi: C.albicans (MIC >200 ug/ml).
Evidence 7 Activity

Activity

MIC
Antifungal
>100 µg/mL

Target

E.cloacae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli ATCC 25922 or ML-35p or 6 clincal strains (1.56-12.5 ug/ml), E.cloacae (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC
Evidence 8 Activity

Activity

MIC
Antifungal
12.5 µg/mL

Target

Enterobacter aerogenes

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ATCC 25922 or ML-35p or 6 clincal strains (1.56-12.5 ug/ml), E.cloacae (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC 3.1-6.25 ug/ml), K. pneumoniae
Evidence 9 Activity

Activity

MIC
Antifungal
6.25-12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

l strains (1.56-12.5 ug/ml), E.cloacae (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC 3.1-6.25 ug/ml), K. pneumoniae (3.1-6.25 ug/ml), Gram+ S. aureus ATCC
Evidence 10 Activity

Activity

MIC
Antifungal
3.1-6.25 µg/mL

Target

H. influenzae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

e (MIC >100 ug/ml), E. aerogenes (MIC 12.5 ug/ml), 4 P. aeruginosa (MIC 6.25-12.5 ug/ml), H. influenzae (MIC 3.1-6.25 ug/ml), K. pneumoniae (3.1-6.25 ug/ml), Gram+ S. aureus ATCC 25923, ATCC 43300 MRSA (MIC 3.125-1
Evidence 11 Activity

Activity

MIC
Antifungal
25 µg/mL

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

iae (3.1-6.25 ug/ml), Gram+ S. aureus ATCC 25923, ATCC 43300 MRSA (MIC 3.125-12.5 ug/ml), E. faecalis ATCC 29212 (MIC 25 ug/ml), and fungi: C.albicans (MIC >200 ug/ml).
Evidence 12 Activity

Activity

MIC
Antifungal
>200 µg/mL

Target

C.albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ATCC 43300 MRSA (MIC 3.125-12.5 ug/ml), E. faecalis ATCC 29212 (MIC 25 ug/ml), and fungi: C.albicans (MIC >200 ug/ml).
Evidence 13 Activity

Activity

1.9% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
1.9% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 14 Activity

Activity

1.1% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
1.1% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 15 Activity

Activity

1.3% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
1.3% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 16 Activity

Activity

5.4% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
5.4% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 17 Activity

Activity

2.9% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
2.9% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 18 Activity

Activity

2.6% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
2.6% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 19 Activity

Activity

2.7% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
2.7% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 20 Activity

Activity

2.8% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
2.8% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 21 Activity

Activity

15% Killing
Toxicity
128 µg/mL
Cytotoxic
15% Killing | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 22 Activity

Activity

0.5% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
0.5% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 23 Activity

Activity

8.7% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
8.7% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 24 Activity

Activity

35% Killing
Toxicity
128 µg/mL
Cytotoxic
35% Killing | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 25 Activity

Activity

5% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo | J Med Chem | 2022
Evidence 26 Activity

Activity

20% Cytotoxicity
Toxicity
128 µg/mL
Cytotoxic
20% Cytotoxicity | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo | J Med Chem | 2022
Evidence 27 Activity

Activity

4.4% Hemolysis
Toxicity
320 µg/mL
Hemolytic Cytotoxic
4.4% Hemolysis | 320 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 28 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Novel Stapling by Lysine Tethering Provides Stable and Low Hemolytic Cationic Antimicrobial Peptides. | J Med Chem | 2020
Evidence 29 Activity

Activity

% Hemolysis
Toxicity
13 %
Hemolytic
Hemolytic_activity: [Ref.22491685] 13% hemolysis at 100 µg/ml , 17% hemolysis at 200 µg/ml , 18% hemolysis at 300 µg/ml , 18.5% hemolysis at 400 µg/ml against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2012 Jun 56(6):3309-17. doi: 10.1128/AAC.06304-11.